Nektar Therapeutics (OQ:NKTR)

Mar 22, 2024 02:00 pm ET
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
Feb 26, 2024 05:00 pm ET
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Jan 03, 2024 05:00 pm ET
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
SAN FRANCISCO, Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until February 9, 2024.
Dec 11, 2023 05:00 pm ET
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
– NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-Resistant Burkitt Lymphoma (BL) Cells –
Nov 07, 2023 03:15 pm ET
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
SAN FRANCISCO, Nov. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023.
Oct 31, 2023 06:00 pm ET
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Oct 13, 2023 08:30 am ET
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –
Oct 02, 2023 09:00 am ET
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation –
Sep 27, 2023 09:00 am ET
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
SAN FRANCISCO, Sept. 27, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBMG").  The study will evaluate Nektar's NKTR-255, a novel interleukin-15 (IL-15) receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy.
Sep 13, 2023 09:00 am ET
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study
Aug 01, 2023 06:00 pm ET
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Jun 12, 2023 06:00 pm ET
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
SAN FRANCISCO, June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 1:20 p.m. Pacific Time.
May 09, 2023 04:15 pm ET
Nektar Therapeutics Reports First Quarter 2023 Financial Results
SAN FRANCISCO, May 9, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023.
Apr 17, 2023 05:00 pm ET
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
-- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs --
Mar 29, 2023 05:44 pm ET
Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600
NEW YORK, March 29, 2023 /PRNewswire/ -- Crane Co. (NYSE:CR) will be added to the S&P MidCap 400 effective prior to the open of trading on Tuesday, April 4, replacing PacWest Bancorp (NASD:PACW) which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Wednesday, April 5. PacWest Bancorp will replace Nektar Therapeutics (NASD:NKTR) in the S&P SmallCap 600 effective prior to the open of trading on Wednesday, April 5. S&P MidCap 400 constituent Crane Holdings Co. (NYSE:CR) is spinning off new Crane in a transaction expected to be completed on April 4
Mar 11, 2023 06:00 pm ET
Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
SAN FRANCISCO, March 11, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not hold any cash deposits or securities at Silicon Valley Bank.  At December 31, 2022, the company had approximately $505 million in cash and investments in marketable securities.
Feb 23, 2023 03:30 pm ET
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
Improvement in SLEDAI-2K score observed as compared to placebo, although study did not meet primary endpoint
Feb 01, 2023 09:42 am ET
Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors’ and officers’ possible violations of state laws.
Jan 04, 2023 08:00 am ET
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
SAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until February 11, 2023.
Dec 29, 2022 11:28 am ET
Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to shareholders. The investigation concerns potential...
Dec 15, 2022 12:34 pm ET
Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Dec 12, 2022 09:05 am ET
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
-- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies --
Dec 05, 2022 07:00 am ET
Nektar Therapeutics to Host Investor & Analyst Event on December 12th
SAN FRANCISCO, Dec. 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST. Nektar management will be joined by Dr. Cameron Turtle, Professor and Chair of Cancer Immunotherapy at the University of Sydney, Australia and Fred Hutchinson Cancer Center affiliate, to discuss the NKTR-255 program and the potential role of IL-15 within the cell therapy landscape.
Nov 10, 2022 08:05 am ET
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
NKTR-288 upregulated MHC Class I and PD-L1 expression on tumors, enhancing anti-tumor activity when combined with anti-PD-1 or anti-PD-L1 antibodies
Nov 09, 2022 08:00 am ET
Nov 03, 2022 04:15 pm ET
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022.
Oct 25, 2022 06:00 pm ET
Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Oct 19, 2022 01:06 pm ET
Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Sep 07, 2022 01:15 am ET
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) C
SAN FRANCISCO, Sept. 7, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as LY3471851 or NKTR-358) in patients with atopic dermatitis (AD) and plaque psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress.
Aug 16, 2022 08:30 am ET
Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma
SAN FRANCISCO, Aug. 16, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on natural killer (NK) cell function and proliferation in multiple myeloma (MM).
Aug 04, 2022 04:15 pm ET
Nektar Therapeutics Reports Second Quarter 2022 Financial Results
SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022.
Jul 26, 2022 06:00 pm ET
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
May 05, 2022 04:15 pm ET
Nektar Therapeutics Reports First Quarter 2022 Financial Results
SAN FRANCISCO, May 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022.
Apr 25, 2022 04:30 pm ET
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs
Apr 23, 2022 05:30 pm ET
Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy M
SAN FRANCISCO, April 23, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College today presented data from several preclinical studies demonstrating the potential of NKTR-255 to enhance the anti-tumor activities of different CAR-T therapies in a variety of cancer preclinical models. Presentations include an oral presentation by Wen Luo, Ph.D., assistant professor of pediatrics at NYMC, on in vivo and in vitro efficacy of NKTR-255 combined with anti-MCAMa CARb modified Natural Killer (NK) cells in several tumor
Apr 22, 2022 08:30 am ET
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan
SAN FRANCISCO, April 22, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m. Pacific Standard Time (PST), to outline a new strategic plan for the company and provide updates for the company's research and development pipeline.
Apr 18, 2022 11:01 am ET
Thinking about buying stock in DiDi Global, Borqs Technologies, Aterian, Nektar Therapeutics, or TG Therapeutics?
NEW YORK, April 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIDI, BRQS, ATER, NKTR, and TGTX.
Apr 14, 2022 04:30 pm ET
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
PRINCETON, N.J. and SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued.
Mar 26, 2022 12:37 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
NEW YORK, March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Mar 16, 2022 08:31 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
NEW YORK , March 16, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Mar 14, 2022 07:05 am ET
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial
SAN FRANCISCO, March 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pacific Standard Time (PST), following this morning's update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study in previously untreated unresectable or metastatic melanoma.
Feb 28, 2022 03:15 pm ET
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
SAN FRANCISCO, Feb. 28, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021.
Feb 17, 2022 05:00 pm ET
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Feb. 17, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday, February 28, 2022, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Jan 05, 2022 08:00 am ET
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
SAN FRANCISCO, Jan. 5, 2022 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 3:00 p.m. Eastern Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until February 11, 2022.
Dec 21, 2021 10:18 am ET
Thinking about buying stock in Naked Brand, Pioneer Power Solutions, Rite Aid, Nektar Therapeutics, or Can Fite Biopharma?
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAKD, PPSI, RAD, NKTR, and CANF.
Dec 15, 2021 08:10 am ET
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis
SAN FRANCISCO, Dec. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored Phase 1b proof-of-concept study of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, in patients with moderate-to-severe atopic dermatitis during its Investment Community Meeting.
Dec 13, 2021 08:00 am ET
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hema
SAN FRANCISCO, Dec. 13, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced two data presentations from the dose-escalation portion of its ongoing Phase 1 study of NKTR-255 in patients with relapsed/refractory hematologic malignancies at the 63rd American Society of Hematology (ASH) Annual Meeting.
Dec 03, 2021 06:51 pm ET
Signature Bank, SolarEdge Technologies and FactSet Research Systems Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Dec. 3, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following index changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 to ensure each index is more representative of its market capitalization range. The changes will be effective prior to the open of trading on Monday, December 20, 2021 to coincide with the quarterly rebalance:
Nov 30, 2021 07:00 am ET
Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of
SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will present data at two upcoming medical meetings for two of its cytokine immuno-oncology programs: IL-2 agonist, bempegaldesleukin (BEMPEG), and IL-15 agonist, NKTR-255. The company will be presenting clinical data for BEMPEG from the ongoing PROPEL study in patients with non-small cell lung cancer (NSCLC) at the 2021 European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress in Geneva, Switzerland from December 8 to December 11, 2021. In addition, two clinical data present
Nov 15, 2021 07:30 am ET
Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.
SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems.
Nov 12, 2021 06:00 am ET
Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nov 09, 2021 07:15 am ET
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar management on Friday, November 12, 2021, at 12:00 p.m. EST during the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The call will be hosted by Nektar management and will include, SITC author and presenter, Dr. Mehmet Altan, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas Anderson Cancer Center and Dr.
Nov 04, 2021 04:15 pm ET
Nektar Therapeutics Reports Third Quarter 2021 Financial Results
SAN FRANCISCO, Nov. 4, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2021.
Oct 26, 2021 06:00 pm ET
Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Sep 22, 2021 09:31 am ET
Thinking about trading options or stock in Ambarella, Robinhood Markets, Lucid Group, Adobe, or Nektar Therapeutics?
NEW YORK, Sept. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMBA, HOOD, LCID, ADBE, and NKTR.
Sep 21, 2021 09:00 am ET
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study
SAN FRANCISCO, Sept. 21, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 (IL-15) receptor agonist, in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma (UC) in the Phase II JAVELIN Bladder Medley study.
Aug 05, 2021 04:15 pm ET
Nektar Therapeutics Reports Second Quarter 2021 Financial Results
SAN FRANCISCO, Aug. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2021.
Jul 27, 2021 06:00 pm ET
Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Jul 19, 2021 09:00 am ET
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
SAN FRANCISCO, July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO). In his role as CMO, Dr. Nuyten will have oversight for the company's clinical strategy and activities, including direct supervision of clinical sciences, clinical operations, data science and systems, medical affairs and clinical pharmacology. Dr. Nuyten will also serve as a member of the Company's Executive Committee. 
Feb 25, 2021 03:15 pm ET
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
SAN FRANCISCO, Feb. 25, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020.
Feb 18, 2021 04:30 pm ET
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Feb. 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2020, on Thursday, February 25, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Feb 18, 2021 08:31 am ET
Thinking about trading options or stock in Nektar Therapeutics, Sleep Number, General Electric, Twilio, or Spirit Airlines?
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKTR, SNBR, GE, TWLO, and SAVE.
Feb 17, 2021 08:31 am ET
Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder?
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, VZ, NKTR, CVX, and EL.
Feb 17, 2021 07:00 am ET
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head an
SAN FRANCISCO, Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) for a Phase 2/3 study of bempegaldesleukin (NKTR-214, BEMPEG), Nektar's investigational IL-2 pathway agent, in combination with Merck's KEYTRUDA® (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (SCCHN) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1).  The
Feb 17, 2021 06:59 am ET
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
SAN FRANCISCO, Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG), an investigational CD122-preferential IL-2–pathway agonist. SFJ Pharmaceuticals is a global drug development company backed by Abingworth and Blackstone Life Sciences.
Feb 01, 2021 08:31 am ET
Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKTR, PFE, AZN, VIR, and ESPR.
Jan 29, 2021 10:15 am ET
Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp?
NEW YORK, Jan. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DDS, INO, LLY, NKTR, and CCL.
Jan 06, 2021 04:00 pm ET
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
SAN FRANCISCO, Jan. 6, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 11:50 a.m. Pacific Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until February 10, 2021.
Jan 05, 2021 03:20 pm ET
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development
SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately. Since 2017, Dr. Kotzin has served as Senior Vice President, Clinical Development and Head of Immunology at Nektar. Wei Lin will be leaving the company to pursue another opportunity.
Dec 22, 2020 07:30 am ET
Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million
SAN FRANCISCO, Dec. 22, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its royalties on future sales of ADYNOVATE, under Nektar's agreement with Baxalta Incorporated, a Takeda company, and MOVANTIK, under Nektar's agreement with AstraZeneca AB. Under the terms of the new Purchase and Sale Agreement, HCR will pay Nektar an aggregate cash payment of $150.0 million by December 31, 2020.
Dec 15, 2020 07:30 am ET
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colore
SAN FRANCISCO, Dec. 15, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the first patient has been dosed in the Phase 1/2 trial of NKTR-255, Nektar's investigational IL-15 pathway agonist, in patients with relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC) at the START Center for Cancer Care in San Antonio, TX. The study is evaluating NKTR-255 plus cetuximab in up to 80 patients at approximately 15 investigator sites in the United States and European Union.
Dec 08, 2020 06:00 am ET
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of EQT, ZYNE, NKTR, and FMO; Shareholders are Encouraged to Contact the Firm
National law firm Barr Law Group is investigating the actions of the officers and board of directors of EQT Corporation, Zynerba Pharmaceuticals, Inc., Nektar Therapeutics, and Fiduciary/Claymore Energy Infrastructure Fund.   If you are a current...
Dec 07, 2020 03:00 pm ET
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced two nonclinical data presentations for NKTR-255, its IL-15 pathway agonist, at the 62nd American Society of Hematology (ASH) Annual Meeting. The presentations include an oral presentation of translational research studies conducted in collaboration with researchers from Dana-Farber Cancer Center. 
Nov 11, 2020 01:00 pm ET
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational agents at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nov 09, 2020 07:00 am ET
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a panel of oncology experts and company management on Wednesday, November 11, 2020, at 4:15 p.m. EST during the 2020 Society for Immunotherapy of Cancer Annual Meeting (SITC). The call will be hosted by Nektar management and will include SITC authors and presenters, Dr. Adi Diab, Associate Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center; Dr. Brendan Curti, Director of the Melanoma Program,
Nov 05, 2020 03:15 pm ET
Nektar Therapeutics Reports Third Quarter 2020 Financial Results
SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today reported financial results for the third quarter ended September 30, 2020.
Nov 04, 2020 09:15 am ET
New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress
SAN FRANCISCO, Nov. 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, currently in development for the treatment of a range of autoimmune disorders, including systemic lupus erythematosus (SLE).
Oct 29, 2020 06:00 pm ET
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress
SAN FRANCISCO, Oct. 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management and Dr. Klatzmann of Sorbonne University on Wednesday, November 4, 2020 at 4:15 p.m. EST. The event will follow Wednesday's virtual release by ACR of the poster presentation of data from Nektar's Phase 1b multiple ascending dose study of NKTR-358, a first-in-class investigational regulatory T cell stimulator, in patients with systemic lupus erythematosus. The poster will be displayed online from Novemb
Oct 28, 2020 06:00 pm ET
Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Oct 27, 2020 07:30 am ET
Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19
SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its investigational IL-2 pathway agent, bempegaldesleukin (BEMPEG, NKTR-214), to be evaluated in a Phase 1b clinical study in adult patients who have been diagnosed with mild COVID-19 infection. The study is designed to evaluate whether BEMPEG's ability to stimulate lymphocyte production could improve treatment regimens for COVID-19 patients.  Enrollment in the Phase 1b, randomized, double-blind, placebo-contr
Aug 06, 2020 04:15 pm ET
Nektar Therapeutics Reports Second Quarter 2020 Financial Results
SAN FRANCISCO, Aug. 6, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.
Jul 28, 2020 06:00 pm ET
Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, July 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Jun 04, 2020 05:00 pm ET
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
SAN FRANCISCO, June 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).
May 29, 2020 05:00 pm ET
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
SAN FRANCISCO, May 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thursday's virtual poster presentation of the data from a Phase 1b multiple ascending dose study of NKTR-358, a first-in-class investigational regulatory T cell stimulator, in patients with systemic lupus erythematosus.
May 22, 2020 08:30 am ET
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
SAN FRANCISCO, May 22, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery on BEMPEG, a CD122-preferential IL-2 pathway agonist, demonstrated that when administered as a monotherapy, it was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization,
May 07, 2020 04:15 pm ET
Nektar Therapeutics Reports First Quarter 2020 Financial Results
SAN FRANCISCO, May 7, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020.
Apr 28, 2020 05:00 pm ET
Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, April 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
Jan 29, 2020 03:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics  - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jan 24, 2020 06:02 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
NEW YORK, Jan. 24, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jan 21, 2020 05:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jan 16, 2020 01:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jan 10, 2020 02:32 pm ET
Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that purchasers of Nektar Therapeutics (NASDAQ: NKTR) filed a derivative complaint against the company's officers and directors for alleged breaches of their fiduciary duties, unjust enrichment, waste of corporate assets, and violations of the Securities Exchange Act
Jan 10, 2020 06:59 am ET
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today
Nov 13, 2019 04:30 pm ET
Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference
SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on Wednesday, November 20, 2019 at 4:00 p.m. Greenwich Mean Time.
Nov 10, 2019 10:00 am ET
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
SAN FRANCISCO, Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic inflammatory conditions.
Nov 09, 2019 04:30 pm ET
Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO, Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nov 06, 2019 03:03 pm ET
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019.
Nov 01, 2019 09:00 am ET
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting
SAN FRANCISCO, Nov. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m. EST in Washington, D.C. during the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The call will be hosted by Nektar management and will also include Dr. Adi Diab, Assistant Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center. The event will follow Dr. Diab's oral presentation on Saturday evening
Oct 30, 2019 05:00 pm ET
Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 30, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Standard Time/2:00 p.m. Pacific Standard Time.
Oct 18, 2019 03:00 pm ET
DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and certain of its officers, on behalf of shareholders...
Oct 17, 2019 11:18 am ET
KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors – NKTR
Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NASDAQ: NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of...
Oct 16, 2019 06:03 pm ET
FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NASDAQ: NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Nektar securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”).
Oct 16, 2019 10:11 am ET
NKTR CLASS ACTION DEADLINE IN 1 DAY: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a motion for appointment as lead plaintiff in a securities class action on behalf of investors that purchased or acquired the securities of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) between February 15, 2019 and August 8, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.
Oct 16, 2019 09:00 am ET
Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
SAN FRANCISCO, Oct. 16, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). The study will also combine NKTR-255 with multiple targeted antibodies, that function through an antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism, to evaluate the safety and efficacy in adults with relapsed or refractory MM. NKTR-255 is designed to activa
Oct 15, 2019 08:49 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all investors that purchased Nektar Therapeutics, Inc. (NASDAQ: NKTR) securities between February 15, 2019 and August 8, 2019 (the “Class Period”). Investors have until October 18, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Oct 15, 2019 05:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Oct 11, 2019 03:00 pm ET
DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar”  or the “Company”) (NASDAQ: NKTR) and certain of its officers, on behalf of shareholders...
Oct 10, 2019 07:39 pm ET
SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NASDAQ:  NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of...
Oct 09, 2019 11:19 am ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in ERI, NKTR, and GVA of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ERI, NKTR, and GVA. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Oct 09, 2019 11:05 am ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action – NKTR
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the “Class Period”) of the important October 18, 2019 lead...
Oct 09, 2019 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors who...
Oct 09, 2019 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of NetApp, Inc. (NASDAQ: NTAP), SAExploration Holdings, Inc. (NASDAQ: SAEX), Nektar Therapeutics, Inc. (NASDAQ: NKTR), and...
Oct 08, 2019 01:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Oct 07, 2019 11:00 am ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
Law Offices of Howard G. Smith reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR)...
Oct 07, 2019 09:00 am ET
Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
SAN FRANCISCO, Oct. 7, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and one in patients with atopic dermatitis. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from reduced numbers and impaired function of immune regulating Treg cells. NKTR-358 works by targeting the interleukin-2 receptor complex to stimulate the proliferation and suppressive function
Oct 04, 2019 03:00 pm ET
Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 03, 2019 11:35 am ET
Zhang Investor Law Reminds Investors of October 18 Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nektar Therapeutics (Nasdaq: NKTR) between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). If you wish to serve...
Oct 02, 2019 09:18 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of NetApp, Inc. (NASDAQ: NTAP), SAExploration Holdings, Inc. (NASDAQ: SAEX), Nektar Therapeutics, Inc. (NASDAQ: NKTR), and...
Oct 02, 2019 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors who...
Oct 02, 2019 10:12 am ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in ERI, NKTR, and GVA of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ERI, NKTR, and GVA. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Oct 02, 2019 08:55 am ET
Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The presentations include an oral session with a presentation of updated data from the PIVOT-02 study of bempegaldesleukin (NKTR-214, bempeg) with nivolumab in patients with first-line metastatic melanoma. The 2019 SITC Annual Meeting is being held from November 6 to November 10, 2019, at the Gaylord National Hotel & Convention C
Oct 01, 2019 08:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Valaris” or the “Company”) (NASDAQ: NKTR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Oct 01, 2019 05:52 pm ET
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NASDAQ:  NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of...
Oct 01, 2019 08:00 am ET
Nektar Announces Key Executive Promotions
SAN FRANCISCO, Oct. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team: 
Sep 27, 2019 07:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action - NKTR
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the “Class Period”) of the important October 18, 2019 lead...
Sep 27, 2019 03:00 pm ET
Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 27, 2019 11:00 am ET
DEADLINE ALERT for ACRS, GTT, JE, and NKTR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 26, 2019 06:21 pm ET
Las Vegas Sands Set to Join S&P 500; Nektar Therapeutics to Join S&P MidCap 400; The Pennant Group to Join S&P SmallCap 600
NEW YORK, Sept. 26, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600:
Sep 26, 2019 05:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
NEW YORK, Sept. 26, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Valaris" or the "Company") (NASDAQ: NKTR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Sep 26, 2019 05:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
NEW YORK, Sept. 26, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Valaris" or the "Company") (NASDAQ: NKTR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Sep 26, 2019 09:58 am ET
Zhang Investor Law Reminds Investors of October 18 Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics- NKTR
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nektar Therapeutics (NKTR) between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). If you wish to serve as lead...
Sep 26, 2019 07:00 am ET
Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy C
SAN FRANCISCO, Sept. 26, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in patients with advanced or metastatic triple-negative breast cancer (TNBC) at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in Paris, France.
Sep 25, 2019 08:06 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Sarepta Therapeutics, and Canada Goose and Encourages Investors to Contac
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics, Inc. (NASDAQ: NKTR), Valaris Plc (NYSE: VAL), Sarepta Therapeutics, Inc. (NASDAQ: SRPT), and Canada Goose...
Sep 24, 2019 11:19 am ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in CARB, NKTR, and GVA of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of CARB, NKTR, and GVA. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Sep 24, 2019 09:02 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange...
Sep 23, 2019 05:47 pm ET
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NASDAQ:  NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of...
Sep 23, 2019 05:00 pm ET
Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference
SAN FRANCISCO, Sept. 23, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that new data from a cohort of patients with metastatic triple-negative breast cancer who were enrolled in the PIVOT-02 study will be presented at the upcoming 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference, which is being held from September 25 to September 28, 2019, at the Espace Grand Arche de la Defense in Paris, France. The PIVOT-02 study is evaluating bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in a range of advanced and/or metastatic solid tumor settings.
Sep 23, 2019 04:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Valaris” or the “Company”) (NASDAQ: NKTR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Sep 20, 2019 03:00 pm ET
Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 20, 2019 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors who...
Sep 18, 2019 07:50 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of NetApp, Inc. (NASDAQ: NTAP), SAExploration Holdings, Inc. (NASDAQ: SAEX), Nektar Therapeutics, Inc. (NASDAQ: NKTR), and...
Sep 17, 2019 09:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Valaris” or the “Company”) (NASDAQ: NKTR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Sep 17, 2019 07:21 pm ET
Kessler Topaz Meltzer & Check, LLP Reminds Nektar Therapeutics Investors of Important Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NASDAQ:  NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of...
Sep 17, 2019 01:29 pm ET
INVESTOR DEADLINES: Bernstein Liebhard LLP Reminds Investors in NKTR and GVA of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of NKTR and GVA. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff...
Sep 17, 2019 08:40 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange...
Sep 13, 2019 03:00 pm ET
Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 12, 2019 06:23 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action - NKTR
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the “Class Period”) of the important October 18, 2019 lead...
Sep 12, 2019 03:32 pm ET
NKTR CLASS ACTION ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics
NEW YORK, Sept. 12, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired the securities of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) between February 15, 2019 and August 8, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.
Sep 12, 2019 02:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Valaris” or the “Company”) (NASDAQ: NKTR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Sep 11, 2019 06:13 pm ET
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NASDAQ:  NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of...
Sep 10, 2019 08:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Canada Goose and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics (NASDAQ: NKTR), Valaris Plc (NYSE: VAL), Burford Capital Limited (Other OTC: BRFRF), and Canada Goose...
Sep 10, 2019 10:20 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange...
Sep 06, 2019 05:52 pm ET
KESSLER TOPAZ MELTZER & CHECK, LLP – Reminds Investors of Securities Fraud Class Action Lawsuit Against NEKTAR THERAPEUTICS – NKTR
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Nektar Therapeutics (NASDAQ:  NKTR)...
Sep 06, 2019 03:00 pm ET
Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Class Action Update - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 05, 2019 06:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Nektar Therapeutics Investors of Important Deadline in Securities Class Action – NKTR
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the “Class Period”) of the important October 18, 2019 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Nektar investors under the federal securities laws.
Sep 04, 2019 07:07 pm ET
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics
The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) (“Nektar”) on behalf of those who purchased or otherwise acquired Nektar securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”).
Sep 04, 2019 06:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Valaris” or the “Company”) (NASDAQ: NKTR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Sep 04, 2019 12:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Textron and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics (NASDAQ: NKTR), Valaris Plc (NYSE: VAL), Burford Capital Limited (Other OTC: BRFRF), and Textron, Inc....
Sep 04, 2019 10:30 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange...
Sep 03, 2019 06:43 pm ET
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR
RADNOR, Pa., Sept. 3, 2019 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Nektar Therapeutics (NASDAQ:  NKTR) ("Nektar") on behalf of those who purchased or otherwise acquired Nektar securities between February 15, 2019 and August 8, 2019, inclusive (the "Class Period").
Aug 30, 2019 06:19 pm ET
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Nektar Therapeutics
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Nektar Therapeutics (NASDAQ:  NKTR)...
Aug 30, 2019 06:00 pm ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
SAN DIEGO, Aug. 30, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased a common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving a
Aug 30, 2019 06:00 pm ET
ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics – NKTR
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the “Class...
Aug 30, 2019 03:00 pm ET
Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Granite Construction Incorporated (GVA) Class Actions - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Aug 29, 2019 01:30 pm ET
ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR
NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Nektar investors under the federal securities laws.
Aug 27, 2019 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Granite Construction, Pluralsight, SAExploration, and Nektar and Encourages Investors to Contact the Fi
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Granite Construction, Inc. (NYSE: GVA), Pluralsight, Inc. (NASDAQ: PS), SAExploration Holdings, Inc. (NASDAQ: SAEX), and...
Aug 26, 2019 04:00 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ:
Aug 26, 2019 01:21 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
Law Offices of Howard G. Smith reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Perio
Aug 23, 2019 03:00 pm ET
INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar”  or the Company”) (NASDAQ: NKTR) and certain of its officers, on behalf of shareholders...
Aug 23, 2019 10:55 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange...
Aug 22, 2019 07:30 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (Nasdaq: NKTR) in the United States District Court for the Northern District of California on behalf of those who...
Aug 22, 2019 03:00 pm ET
INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019
NEW YORK, Aug. 22, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar"  or the Company") (NASDAQ: NKTR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nektar securities between February 15, 2019 through August 8, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/nktr.
Aug 22, 2019 10:29 am ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ:
Aug 21, 2019 04:52 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ:
Aug 21, 2019 04:35 pm ET
NEKTAR THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Northern Distr
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit  has been filed in the United States District Court for the Northern District of California on behalf of all investors that purchased Nektar...
Aug 21, 2019 11:01 am ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics – NKTR
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Nektar investors under the federal securities laws.
Aug 20, 2019 08:00 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm
NEW YORK, Aug. 20, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all investors that purchased Nektar Therapeutics, Inc. (NASDAQ: NKTR) securities between February 15, 2019 and August 8, 2019 (the "Class Period").  Investors have until October 18, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Aug 20, 2019 01:31 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). Nektar investors have until October 18, 2019 to file a lead plaintiff motion.
Aug 19, 2019 09:43 pm ET
Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR)
Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Damiba v. Nektar Therapeutics, et. al., (Case No. 3:19-cv-05173) on behalf of persons and/or entities that acquired Nektar Therapeutics (NASDAQ:
Aug 15, 2019 08:35 pm ET
Bragar Eagel & Squire, P.C. is Investigating Nektar Therapeutics, Inc. (NASDAQ: NKTR) on Behalf of Stockholders and Encourages Nektar Investors to Contact the Firm
NEW YORK, Aug. 15, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against Nektar Therapeutics, Inc. (NASDAQ: NKTR). Our investigation concerns whether Nektar has violated the federal securities laws and/or engaged in other unlawful business practices.
Aug 14, 2019 10:32 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the...
Aug 14, 2019 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nektar Therapeutics (NKTR)
NEW YORK, Aug. 14, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Investors who purchased Nektar stock are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nktr.       
Aug 13, 2019 03:06 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ:
Aug 10, 2019 01:33 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ:
Aug 09, 2019 06:30 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ:
Aug 09, 2019 03:44 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company and its officers’ possible violations of federal securities laws.
Aug 09, 2019 11:58 am ET
Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Nektar Therapeutics
MILWAUKEE, Aug. 9, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating possible securities fraud claims against Nektar (Nasdaq: NKTR) resulting from inaccurate statements Nektar made regarding its business practices, financial statements and prospects.
Aug 08, 2019 04:15 pm ET
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019
SAN FRANCISCO, Aug. 8, 2019 /PRNewswire/ --  Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2019.
Aug 01, 2019 07:00 am ET
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients w
SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb's Opdivo® (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma. The Breakthrough Therapy Designation is based on clinical data which were recently reported at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeti
Jul 30, 2019 05:00 pm ET
Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, July 30, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 8, 2019, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Daylight Time/2:00 p.m. Pacific Daylight Time.
May 23, 2019 08:00 am ET
Nektar Announces the Launch of Inheris Biopharma, Inc.
SAN FRANCISCO, May 23, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will be responsible for launch preparation and commercialization for NKTR-181, a novel, first-in-class, investigational opioid molecule. NKTR-181 is currently under review with the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) target action date of August 29, 2019. Inheris will also lead development of several Nektar preclinical CNS assets.
May 15, 2019 05:00 pm ET
Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting
SAN FRANCISCO, May 15, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 31 to June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois. The abstracts published in advance of the ASCO Annual Meeting were made available at 5:00 p.m. Eastern Daylight Time today on the ASCO meeting website at http://www.abstract.asco.org.
May 08, 2019 04:10 pm ET
Nektar Therapeutics Reports Financial Results for the First Quarter of 2019
SAN FRANCISCO, May 8, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019.
May 01, 2019 05:00 pm ET
Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, May 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Daylight Time/2:00 p.m. Pacific Daylight Time.
Apr 02, 2019 03:00 pm ET
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
SAN FRANCISCO, April 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research (AACR) Annual Meeting 2019.  The meeting is being held on March 29 to April 3, 2019 at the Georgia World Congress Center in Atlanta.  
Apr 01, 2019 04:15 pm ET
Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
OSLO, Norway and SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist. These data were presented today in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2019.
Mar 06, 2019 03:30 pm ET
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 9:20 a.m. Eastern Time.
Mar 05, 2019 08:15 am ET
Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), Aimmune Therapeutics, Inc. (NASDAQ:AIMT),...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.